D3 Bio - 2025 Company Profile, Funding & Competitors

Q: Where is D3 Bio located?

D3 Bio is located in Shanghai, China .

D3 Bio is a series A company based in Shanghai (China), founded in 2018 by . It operates as a Developer novel therapeutics for cancer. D3 Bio has raised $262M in funding from investors like Temasek, Matrix Partners China and . The company has 3104 active competitors, including 1092 funded and 730 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Moderna and BeiGene.

Company Details

Developer novel therapeutics for cancer. The company is focusing on developing innovative medicines in oncology and immunology. The company's pipeline include D3S-001 for the treatment of advanced unresectable or metastatic colorectal cancers.

Key Metrics

Founded Year

2018

Location

Shanghai, China

Stage

Series A

Total Funding

in 2 rounds

Latest Funding Round

Investors

Temasek & 5 more

Ranked

769^th among 3104 active competitors

Similar Companies

Jazz Pharmaceuticals &

D3 Bio has raised a total funding of $262M over 2 rounds. Its first funding round was on Nov 17, 2020. Its latest funding round was a Series A round on Apr 08, 2024 for $62M. 3 investors participated in its latest round, which includes Medicxi, Temasek, Boyu Capital and WuXi AppTec.

D3 Bio has 6 institutional investors including Temasek, Matrix Partners China and .

Here is the list of recent funding rounds of D3 Bio:

Date of funding	Funding Amount	Round Name	Post money valuation	Revenue multiple	Investors
Apr 08, 2024	$62M	Series A	5783929	4735468	Medicxi, WuXi AppTec, and
Nov 17, 2020	$200M	Series A	9872946	2963389	Boyu Capital, Matrix Partners China, and

Access funding benchmarks and valuations. Sign up today!

View details of D3 Bio's funding rounds and investors

The founders of D3 Bio is . is the CEO of D3 Bio.

View details of D3 Bio's Founder profiles and Board Members

Top competitors of D3 Bio include Jazz Pharmaceuticals, Moderna and BeiGene. Here is the list of Top 10 competitors of D3 Bio, ranked by 秘密研究所 score :

Overall Rank	Company Details	Short Description	Total Funding	Investors	秘密研究所 Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of therapeutics for cancer and neurological disorders	$265M	Versant Ventures, Bellevue Healthcare Trust听&补尘辫;听	81/100
2nd	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	CEPI, Three Fields Capital听&补尘辫;听	80/100
3rd	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Yuan Ming Capital, CPE听&补尘辫;听	78/100
4th	Recursion 2013, United States, Public	Developer of AI-enabled drug discovery and development platform	$452M	Samsara BioCapital, 听&补尘辫;听	77/100
5th	Advanced Accelerator Applications 2002, Saint Genis Pouilly (France), Acquired	Novartis company, developing molecular nuclear medicine theranostics	$56.1M	Vivo Capital, Naxicap听&补尘辫;听	77/100
6th	Incyte 1991, Wilmington (United States), Public	Developer of small molecules for the treatment of different cancer and skin diseases	-	Ridgeback Capital Management, CHL Medical Partners听&补尘辫;听	73/100
7th	Revolution Medicines 2014, Redwood City (United States), Public	Developer of therapies for treating cancer	$181M	Gen 1 Capital, Vivo Capital听&补尘辫;听	72/100
8th	Blueprint Medicines 2008, Cambridge (United States), Public	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Cowen, Redmile Group听&补尘辫;听	71/100
9th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Pappas Capital, Delos Capital Partners听&补尘辫;听	71/100
10th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Mizuho Securities Principal Investment, Roche听&补尘辫;听	71/100
769th	2018, Shanghai (China), Series A	Developer novel therapeutics for cancer	$262M	Medicxi, Temasek听&补尘辫;听	42/100